PREFERENCES OF PEOPLE LIVING WITH HIV FOR INJECTABLE VERSUS ORAL ANTIRETROVIRAL THERAPY (ART) IN CHINA: A DISCRETE CHOICE EXPERIMENT (DCE...

Author(s)

Christina Donatti, PhD1, EUGENA STAMULI, BSc, MSc2, Mickael HENRY, MSc3, Ana Maria Rodriguez-Leboeuf, BSc, MSc, PhD4, Melanie Schroeder, BSc, MASc5.
1ViiV Healthcare, TWICKENHAM, United Kingdom, 2IQVIA HELLAS S.A., Athens, Greece, 3IQVIA, Paris, France, 4IQVIA, Madrid, Spain, 5ViiV Healthcare, London, United Kingdom.
OBJECTIVES: ART advancements have expanded options for people living with HIV. This study evaluated preferences of people living with HIV in China for attributes of oral and long-acting injectable (LAI) ART.
METHODS: In a two-step DCE-based survey, adults living with HIV receiving ART evaluated hypothetical ART profiles, including administration mode/frequency/setting, injection-related side effects (SEs), and general SE probability. Participants first chose between two LAI and one oral ART profiles; if oral was selected, a subsequent choice between the two LAI profiles followed. Oral treatments varied by general SE probability and frequency (daily/weekly). Respondents were recruited via online panels and provider referrals. Using a fractional factorial design, 16 choice-tasks were generated. Preference weights were estimated using a random parameter logit-model, and conditional relative importance scores quantified attribute influence on choices.
RESULTS: Among 150 respondents (male: 74.0%; heterosexual: 93.3%; Han: 81.3%), LAI was chosen in 94.0%, 96.7%, and 97.2% of matched profiles when the oral comparator had 0%, 5%, or 10% SE probability. For step one, general SE and administration mode accounted for ~66% of decision-making. Strong preferences included: subcutaneous injections (β=0.949, P<0.0001); 6-month injection-interval (β=0.562, P<0.0001); mild injection site pain (β=0.375, P<0.0001); skin colour changes and/or swelling (coin-sized) lasting 1-3 days (β=0.138, P=0.0066); nodules with 20% chance but lasting only 2-4 weeks (β=0.266, P<0.0001) or 2-3 months (β=0.257, P<0.0001); and 0% SE probability (β=1.005, P<0.0001). Dispreferences (β<0; P<0.05) included: oral therapies; injections every 2 or 4 months; moderate/severe injection pain; skin colour changes and/or swelling (credit-card sized) lasting ≤10 days; 50% nodule probability lasting 2-3 or 6 months; and general SE risk ≥5%. No significant preference for administration setting was observed.
CONCLUSIONS: People living with HIV in China preferred LAI over oral ART, driven by minimising SE and longer dosing intervals. These preferences can inform regulatory decisions and shared decision‑making.

Conference/Value in Health Info

2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand

Value in Health, Volume 55, Issue S1

Code

PCR21

Topic

Patient-Centered Research

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×